BioSpace News Archive

“Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights.

Moderna, Inc. announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec that will support a long-term strategic partnership with the Government of Canada to enhance pandemic preparedness.

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting.

Rising prevalence of chronic diseases and favourable government initiatives to improve healthcare infrastructure are the key factors driving industry growth.

Increasing launch of cost-efficient generic epinephrine products, growing incidence of anaphylaxis, and rising demand for epinephrine injections to treat cardiac arrest and asthma are some key factors driving market growth.

Rising prevalence of chronic diseases, such as cancer and diabetes, and growing adoption of advanced diagnostic techniques are predicted to fuel market growth.

Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors driving market revenue growth.

GENFIT announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission, as well as the availability of preparatory documents for its annual shareholders meeting on Wednesday May 25, 2022.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m. Pacific Time.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA approved inducement grants of stock options to purchase an aggregate of 50,950 shares of its common stock to 13 newly-hired employees, with a grant date of April 27, 2022.